Celldex Therapeutics (CLDX) Stock Price, News & Analysis

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CLDX shares.
View CLDX analyst ratings or view top-rated stocks.

5 equities research analysts have issued 1-year target prices for Celldex Therapeutics' shares. Their CLDX share price targets range from $27.00 to $90.00. On average, they expect the company's share price to reach $66.00 in the next twelve months. This suggests a possible upside of 73.8% from the stock's current price.
View analysts price targets for CLDX or view top-rated stocks among Wall Street analysts.

Celldex Therapeutics' stock was trading at $39.66 on January 1st, 2024. Since then, CLDX stock has decreased by 4.2% and is now trading at $37.98.
View the best growth stocks for 2024 here.

Celldex Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 6,560,000 shares, an increase of 11.2% from the March 15th total of 5,900,000 shares. Based on an average daily volume of 952,500 shares, the days-to-cover ratio is presently 6.9 days.
View Celldex Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CLDX earnings forecast.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its quarterly earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.19. The biopharmaceutical company had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 41.06% and a negative net margin of 2,054.46%.

ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Principal Healthcare Innovators ETF (BTEC).

Celldex Therapeutics shares reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

Celldex Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Mirador Capital Partners LP (0.19%), Overbrook Management Corp (0.01%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Diane C Young, Elizabeth Crowley, Freddy A Jimenez, Samuel Bates Martin and Sarah Cavanaugh.
View institutional ownership trends.

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.